Literature DB >> 16289943

Selected neurotrophins, neuropeptides, and cytokines: developmental trajectory and concentrations in neonatal blood of children with autism or Down syndrome.

Phillip G Nelson1, Thea Kuddo, Eun Young Song, James M Dambrosia, Shawn Kohler, Gowri Satyanarayana, Cassandra Vandunk, Judith K Grether, Karin B Nelson.   

Abstract

Using a double-antibody immunoaffinity assay (Luminex) and ELISA technology, we measured concentrations of certain neurotrophins, neuropeptides, and cytokines in pooled samples (one to three subjects per sample) eluted from archived neonatal blood of children with later-diagnosed autism, Down syndrome, very preterm birth, or term control infants. We also measured analytes in blood from healthy adult controls. Case or control status for infant subjects was ascertained by retrospective review of service agency medical records. We observed inhibitory substances in eluates from archived bloodspots, especially marked for measurement of BDNF. Concentrations in control subjects differed by age: BDNF rose markedly with age, while NT-3 and NT-4/5 concentrations were lower in adults than in newborn infants. IL-8 concentrations were higher in newborn infants, preterm and term, than in adults. Considered by diagnostic group, total protein was higher in Down syndrome than in either autism or control subjects. In infants with Down syndrome, concentrations of IL-8 levels were higher than in controls, whether or not corrected for total protein; NT-3 and CGRP were lower and VIP higher. In samples from autistic subjects, NT-3 levels were significantly lower than controls and an increase in VIP approached statistical significance. Concentrations of NT-4/5 and CGRP were correlated in infants with autism but not in Down syndrome or controls. Some of these results differ from earlier findings using a single-antibody recycling immunoaffinity chromatography (RIC) system. We discuss interrelationships of VIP, NT-3 and IL-8 and their potential relevance to features of the neuropathology of autism or Down syndrome.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16289943     DOI: 10.1016/j.ijdevneu.2005.10.003

Source DB:  PubMed          Journal:  Int J Dev Neurosci        ISSN: 0736-5748            Impact factor:   2.457


  48 in total

1.  Reduction in retinal nerve fiber layer thickness in young adults with autism spectrum disorders.

Authors:  Leonardo Emberti Gialloreti; Matteo Pardini; Francesca Benassi; Sara Marciano; Mario Amore; Maria Giulia Mutolo; Maria Cristina Porfirio; Paolo Curatolo
Journal:  J Autism Dev Disord       Date:  2014-04

Review 2.  Early pharmacological treatment of autism: a rationale for developmental treatment.

Authors:  Terrence C Bethea; Linmarie Sikich
Journal:  Biol Psychiatry       Date:  2007-02-15       Impact factor: 13.382

3.  Age-related changes in plasma levels of BDNF in Down syndrome patients.

Authors:  Giada Dogliotti; Emanuela Galliera; Federico Licastro; Massimiliano M Corsi
Journal:  Immun Ageing       Date:  2010-01-25       Impact factor: 6.400

4.  Newborn screening for autism: in search of candidate biomarkers.

Authors:  Gerald J Mizejewski; Barbara Lindau-Shepard; Kenneth A Pass
Journal:  Biomark Med       Date:  2013-04       Impact factor: 2.851

Review 5.  From loci to networks and back again: anomalies in the study of autism.

Authors:  Ralph-Axel Müller
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

Review 6.  Exploring the multifactorial nature of autism through computational systems biology: calcium and the Rho GTPase RAC1 under the spotlight.

Authors:  Fares Zeidán-Chuliá; José Luiz Rybarczyk-Filho; Alla B Salmina; Ben-Hur Neves de Oliveira; Mami Noda; José Cláudio F Moreira
Journal:  Neuromolecular Med       Date:  2013-03-02       Impact factor: 3.843

7.  Neurotensin is increased in serum of young children with autistic disorder.

Authors:  Asimenia Angelidou; Konstantinos Francis; Magdalini Vasiadi; Konstantinos-Dionysios Alysandratos; Bodi Zhang; Athanasios Theoharides; Lefteris Lykouras; Kyriaki Sideri; Dimitrios Kalogeromitros; Theoharis C Theoharides
Journal:  J Neuroinflammation       Date:  2010-08-23       Impact factor: 8.322

8.  Increase in cerebellar neurotrophin-3 and oxidative stress markers in autism.

Authors:  Elizabeth M Sajdel-Sulkowska; Ming Xu; Noriyuki Koibuchi
Journal:  Cerebellum       Date:  2009-04-09       Impact factor: 3.847

9.  Serum protein profiling and proteomics in autistic spectrum disorder using magnetic bead-assisted mass spectrometry.

Authors:  Regina Taurines; Edward Dudley; Alexander C Conner; Julia Grassl; Thomas Jans; Frank Guderian; Claudia Mehler-Wex; Andreas Warnke; Manfred Gerlach; Johannes Thome
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-09-27       Impact factor: 5.270

10.  Neurodevelopmental effects of chronic exposure to elevated levels of pro-inflammatory cytokines in a developing visual system.

Authors:  Ryan H Lee; Elizabeth A Mills; Neil Schwartz; Mark R Bell; Katherine E Deeg; Edward S Ruthazer; Nicholas Marsh-Armstrong; Carlos D Aizenman
Journal:  Neural Dev       Date:  2010-01-12       Impact factor: 3.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.